Last reviewed · How we verify
CHRONO-INDOCID
At a glance
| Generic name | CHRONO-INDOCID |
|---|---|
| Also known as | Indomethacin |
| Sponsor | Genfit |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHRONO-INDOCID CI brief — competitive landscape report
- CHRONO-INDOCID updates RSS · CI watch RSS
- Genfit portfolio CI